Apoptotic resistance in chronic lymphocytic leukemia and therapeutic perspectives

References

• Kipps TJ, Stevenson FK, Wu CJ. Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017;3:16096.
   PubMed Web of Science ®Google Scholar
• Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2017;92:946–965.
   PubMed Web of Science ®Google Scholar
• Bagacean C, Zdrenghea M, Tempescul A, et al. Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises. Immunotherapy. 2016;8:569–581.
   PubMed Web of Science ®Google Scholar
• Mato AR, Thompson M, Allan JN, et al. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica. 2018;103:1511–1517.
   PubMed Web of Science ®Google Scholar
• Mauro FR, Caputo MD, Rosati S, et al. Balancing efficacy and toxicity of targeted agents currently used for the treatment of patients with chronic lymphocytic leukemia. Expert Rev Hematol. 2018;11:601–611.
   PubMed Web of Science ®Google Scholar
• Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 2006;25:4798–4811.
   PubMed Web of Science ®Google Scholar
• Bouchon A, Krammer PH, Walczak H. Critical role for mitochondria in B cell receptor-mediated apoptosis. Eur J Immunol. 2000;30:69–77.
   PubMed Web of Science ®Google Scholar
• Strasser A, Harris AW, Corcoran LM, et al. Bcl-2 expression promotes B- but not T-lymphoid development in scid mice. Nature. 1994;368:457–460.
   PubMed Web of Science ®Google Scholar
• Vandenabeele P, Declercq W, Vanhaesebroeck B, et al. Both TNF receptors are required for TNF-mediated induction of apoptosis in PC60 cells. J Immunol. 1995;154:2904–2913.
   PubMed Web of Science ®Google Scholar
• Edlich F. BCL-2 proteins and apoptosis: Recent insights and unknowns. Biochem Biophys Res Commun. 2018;500:26–34.
   PubMed Web of Science ®Google Scholar
• Dlugosz PJ, Billen LP, Annis MG, et al. Bcl-2 changes conformation to inhibit Bax oligomerization. Embo J. 2006;25:2287–2296.
   PubMed Web of Science ®Google Scholar
• Ichim G, Lopez J, Ahmed SU, et al. Limited mitochondrial permeabilization causes DNA damage and genomic instability in the absence of cell death. Mol Cell. 2015;57:860–872.
   PubMed Web of Science ®Google Scholar
• Giampazolias E, Zunino B, Dhayade S, et al. Mitochondrial permeabilization engages NF-kappaB-dependent anti-tumour activity under caspase deficiency. Nat Cell Biol. 2017;19:1116–1129.
   PubMed Web of Science ®Google Scholar
• Zhong F, Harr MW, Bultynck G, et al. Induction of Ca²+-driven apoptosis in chronic lymphocytic leukemia cells by peptide-mediated disruption of Bcl-2-IP3 receptor interaction. Blood. 2011;117:2924–2934.
   PubMed Web of Science ®Google Scholar
• Gross A, Katz SG. Non-apoptotic functions of BCL-2 family proteins. Cell Death Differ. 2017;24:1348–1358.
   PubMed Web of Science ®Google Scholar
• Haupt S, Berger M, Goldberg Z, et al. Apoptosis - the p53 network. J Cell Sci. 2003;116:4077–4085.
   PubMed Web of Science ®Google Scholar
• Fabbri M, Bottoni A, Shimizu M, et al. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA. 2011;305:59–67.
   PubMed Web of Science ®Google Scholar
• Zhu DX, Zhu W, Fang C, et al. miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. Carcinogenesis. 2012;33:1294–1301.
   PubMed Web of Science ®Google Scholar
• Chen L, Widhopf G, Huynh L, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2002;100:4609–4614.
   PubMed Web of Science ®Google Scholar
• Wagner M, Oelsner M, Moore A, et al. Integration of innate into adaptive immune responses in ZAP-70-positive chronic lymphocytic leukemia. Blood. 2016;127:436–448.
   PubMed Web of Science ®Google Scholar
• zum Buschenfelde CM, Wagner M, Lutzny G, et al. Recruitment of PKC-betaII to lipid rafts mediates apoptosis-resistance in chronic lymphocytic leukemia expressing ZAP-70. Leukemia. 2010;24:141–152.
   PubMed Web of Science ®Google Scholar
• Eichhorn JM, Sakurikar N, Alford SE, et al. Critical role of anti-apoptotic Bcl-2 protein phosphorylation in mitotic death. Cell Death Dis. 2013;4:e834.
   PubMed Web of Science ®Google Scholar
• Song T, Chai G, Liu Y, et al. Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding. Br J Pharmacol. 2016;173:471–483.
   PubMed Web of Science ®Google Scholar
• Vogler M, Butterworth M, Majid A, et al. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood. 2009;113:4403–4413.
   PubMed Web of Science ®Google Scholar
• Wei Y, Pattingre S, Sinha S, et al. JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy. Mol Cell. 2008;30:678–688.
   PubMed Web of Science ®Google Scholar
• Lin K, Farahani M, Yang Y, et al. Loss of MIR15A and MIR16-1 at 13q14 is associated with increased TP53 mRNA, de-repression of BCL2 and adverse outcome in chronic lymphocytic leukaemia. Br J Haematol. 2014;167:346–355.
   PubMed Web of Science ®Google Scholar
• Bagacean C, Le Dantec C, Berthou C, et al. Combining cytogenetic and epigenetic approaches in chronic lymphocytic leukemia improves prognosis prediction for patients with isolated 13q deletion. Clin Epigenetics. 2017;9:122.
   PubMed Web of Science ®Google Scholar
• Stankovic T, Weber P, Stewart G, et al. Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. Lancet. 1999;353:26–29.
   PubMed Web of Science ®Google Scholar
• Guieze R, Wu CJ. Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia. Blood. 2015;126:445–453.
   PubMed Web of Science ®Google Scholar
• Knittel G, Rehkamper T, Korovkina D, et al. Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia. Nat Commun. 2017;8:153.
   PubMed Web of Science ®Google Scholar
• Maddocks KJ, Ruppert AS, Lozanski G, et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 2015;1:80–87.
   PubMed Web of Science ®Google Scholar
• Herling CD, Abedpour N, Weiss J, et al. Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia. Nat Commun. 2018;9:727.
   PubMed Web of Science ®Google Scholar
• Kulis M, Heath S, Bibikova M, et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet. 2012;44:1236–1242.
   PubMed Web of Science ®Google Scholar
• Bagacean C, Zdrenghea M, Dantec CL, et al. DNA demethylation marks in chronic lymphocytic leukemia: it is time to let the cat out of the bag. Future Sci OA. 2018;4:FSO265.
   PubMed Web of Science ®Google Scholar
• Bagacean C, Tempescul A, Le Dantec C, et al. Alterations in DNA methylation/demethylation intermediates predict clinical outcome in chronic lymphocytic leukemia. Oncotarget. 2017;8:65699–65716.
   PubMedGoogle Scholar
• Hanada M, Delia D, Aiello A, et al. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood. 1993;82:1820–1828.
   PubMed Web of Science ®Google Scholar
• Wolf C, Garding A, Filarsky K, et al. NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib. Int J Cancer. 2018;142:322–333.
   PubMed Web of Science ®Google Scholar
• Kushwaha G, Dozmorov M, Wren JD, et al. Hypomethylation coordinates antagonistically with hypermethylation in cancer development: a case study of leukemia. Hum Genomics. 2016;10:18.
   PubMed Web of Science ®Google Scholar
• Calissano C, Damle RN, Marsilio S, et al. Intraclonal complexity in chronic lymphocytic leukemia: fractions enriched in recently born/divided and older/quiescent cells. Mol Med. 2011;17:1374–1382.
   PubMed Web of Science ®Google Scholar
• Coscia M, Pantaleoni F, Riganti C, et al. IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. Leukemia. 2011;25:828–837.
   PubMed Web of Science ®Google Scholar
• Herndon TM, Chen SS, Saba NS, et al. Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood. Leukemia. 2017;31:1340–1347.
   PubMed Web of Science ®Google Scholar
• Burger JA, Tsukada N, Burger M, et al. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. 2000;96:2655–2663.
   PubMed Web of Science ®Google Scholar
• Richardson SJ, Matthews C, Catherwood MA, et al. ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2006;107:3584–3592.
   PubMed Web of Science ®Google Scholar
• Deaglio S, Vaisitti T, Aydin S, et al. In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. Blood. 2006;108:1135–1144.
   PubMed Web of Science ®Google Scholar
• Deaglio S, Vaisitti T, Aydin S, et al. CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. Blood. 2007;110:4012–4021.
   PubMed Web of Science ®Google Scholar
• Ysebaert L, Fournie JJ. Genomic and phenotypic characterization of nurse-like cells that promote drug resistance in chronic lymphocytic leukemia. Leuk Lymphoma. 2011;52:1404–1406.
   PubMed Web of Science ®Google Scholar
• Jia L, Clear A, Liu FT, et al. Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia. Blood. 2014;123:1709–1719.
   PubMed Web of Science ®Google Scholar
• Poggi A, Prevosto C, Catellani S, et al. Engagement of CD31 delivers an activating signal that contributes to the survival of chronic lymphocytic leukaemia cells. Br J Haematol. 2010;151:252–264.
   PubMed Web of Science ®Google Scholar
• Filip AA, Ciseł B, Wąsik-Szczepanek E. Guilty bystanders: nurse-like cells as a model of microenvironmental support for leukemic lymphocytes. Clin Exp Med. 2015;15:73–83.
   PubMed Web of Science ®Google Scholar
• Hoellenriegel J, Meadows SA, Sivina M, et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011;118:3603–3612.
   PubMed Web of Science ®Google Scholar
• Hoellenriegel J, Coffey GP, Sinha U, et al. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia. 2012;26:1576–1583.
   PubMed Web of Science ®Google Scholar
• Del Gaizo Moore V, Brown JR, Certo M, et al. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest. 2007;117:112–121.
   PubMed Web of Science ®Google Scholar
• Vogler M, Furdas SD, Jung M, et al. Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood. Clin Cancer Res. 2010;16:4217–4225.
   PubMed Web of Science ®Google Scholar
• O'Brien S, Moore JO, Boyd TE, et al. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2007;25:1114–1120.
   PubMed Web of Science ®Google Scholar
• O'Brien S, Moore JO, Boyd TE, et al. 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol. 2009;27:5208–5212.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012;30:488–496.
   PubMed Web of Science ®Google Scholar
• Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202–208.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:311–322.
   PubMed Web of Science ®Google Scholar
• Anderson MA, Tam C, Lew TE, et al. Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. Blood. 2017;129:3362–3370.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378:1107–1120.
   PubMed Web of Science ®Google Scholar
• Rogers KA, Huang Y, Ruppert AS, et al. Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia. Blood. 2018;132:1568–1572.
   PubMed Web of Science ®Google Scholar
• Choudhary GS, Al-Harbi S, Mazumder S, et al. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies. Cell Death Dis. 2015;6:e1593.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Huang D. Targeting BCL2 with BH3 mimetics: Basic science and clinical application of venetoclax in chronic lymphocytic leukemia and related B cell malignancies. Clin Pharmacol Ther. 2017;101:89–98.
   PubMed Web of Science ®Google Scholar
• Woodland RT, Fox CJ, Schmidt MR, et al. Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival. Blood 2008;111:750–760.
   PubMed Web of Science ®Google Scholar
• Paiva C, Rowland TA, Sreekantham B, et al. SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia. Haematologica. 2017;102:1890–1900.
   PubMed Web of Science ®Google Scholar
• Frank DA, Mahajan S, Ritz J. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J Clin Invest. 1997;100:3140–3148.
   PubMed Web of Science ®Google Scholar
• Garaud S, Taher TE, Debant M, et al. CD5 expression promotes IL-10 production through activation of the MAPK/Erk pathway and upregulation of TRPC1 channels in B lymphocytes. Cell Mol Immunol. 2018;15:158–170.
   PubMed Web of Science ®Google Scholar
• Ferrer G, Montserrat E. Critical molecular pathways in CLL therapy. Mol Med. 2018;24:9.
   PubMed Web of Science ®Google Scholar
• Tahir SK, Smith ML, Hessler P, et al. Potential mechanisms of resistance to venetoclax and strategies to circumvent it. BMC Cancer. 2017;17:399.
   PubMed Web of Science ®Google Scholar
• Blombery P, Anderson MA, Gong JN, et al. Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discov. 2018;9(3):342–353.
   PubMed Web of Science ®Google Scholar
• Blunt MD, Koehrer S, Dobson RC, et al. The dual Syk/JAK inhibitor cerdulatinib antagonizes B-cell receptor and microenvironmental signaling in chronic lymphocytic leukemia. Clin Cancer Res. 2017;23:2313–2324.
   PubMed Web of Science ®Google Scholar
• Bojarczuk K, Sasi BK, Gobessi S, et al. BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199. Blood. 2016;127:3192–3201.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Kitada S, Flinn IW, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 2002;99:1038–1043.
   PubMed Web of Science ®Google Scholar
• Honeychurch J, Alduaij W, Azizyan M, et al. Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. Blood. 2012;119:3523–3533.
   PubMed Web of Science ®Google Scholar
• Choudhary GS, Tat TT, Misra S, et al. Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics. Oncotarget. 2015;6:16912–16925.
   PubMed Web of Science ®Google Scholar
• Larrayoz M, Blakemore SJ, Dobson RC, et al. The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1. Leukemia. 2016;30:351–360.
   PubMed Web of Science ®Google Scholar
• Wan Y, Dai N, Tang Z, et al. Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents. Eur J Med Chem. 2018;146:471–482.
   PubMed Web of Science ®Google Scholar
• Valentin R, Grabow S, Davids MS. The rise of apoptosis: targeting apoptosis in hematologic malignancies. Blood. 2018;132:1248–1264.
   PubMed Web of Science ®Google Scholar
• Ruefli-Brasse A, Reed JC. Therapeutics targeting Bcl-2 in hematological malignancies. Biochem J. 2017;474:3643–3657.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Ma S, Brander DM, et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol. 2017;18:230–240.
   PubMed Web of Science ®Google Scholar
• Fischer K, Al-Sawaf O, Fink AM, et al. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood. 2017;129:2702–2705.
   PubMed Web of Science ®Google Scholar
• Cramer P, von Tresckow J, Bahlo J, et al. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19:1215–1228.
   PubMed Web of Science ®Google Scholar
• Kipps TJ, Eradat H, Grosicki S, et al. A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2015;56:2826–2833.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Advani RH, Kahl BS, et al. Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies. Br J Haematol. 2015;170:669–678.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial. J Clin Oncol. 2018;36:1973–1980.
   PubMed Web of Science ®Google Scholar
• Hallaert DY, Jaspers A, van Noesel CJ, et al. c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. Blood. 2008;112:5141–5149.
   PubMed Web of Science ®Google Scholar
• Tromp JM, Geest CR, Breij EC, et al. Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia. Clin Cancer Res. 2012;18:487–498.
   PubMed Web of Science ®Google Scholar
• Kitada S, Zapata JM, Andreeff M, et al. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol. 1999;106:995–1004.
   PubMed Web of Science ®Google Scholar
• Smit LA, Hallaert DY, Spijker R, et al. Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood. 2007;109:1660–1668.
   PubMed Web of Science ®Google Scholar
• Tromp JM, Tonino SH, Elias JA, et al. Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering. Oncogene. 2010;29:5071–5082.
   PubMed Web of Science ®Google Scholar
• Wild J, Schmiedel BJ, Maurer A, et al. Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis. Leukemia. 2015;29:1676–1683.
   PubMed Web of Science ®Google Scholar
• Petlickovski A, Laurenti L, Li X, et al. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood. 2005;105:4820–4827.
   PubMed Web of Science ®Google Scholar
• Tonino SH, Spijker R, Luijks DM, et al. No convincing evidence for a role of CD31-CD38 interactions in the pathogenesis of chronic lymphocytic leukemia. Blood. 2008;112:840–843.
   PubMed Web of Science ®Google Scholar
• Benkisser-Petersen M, Buchner M, Dorffel A, et al. Spleen tyrosine kinase is involved in the CD38 signal transduction pathway in chronic lymphocytic leukemia. PLoS One. 2016;11:e0169159.
   PubMed Web of Science ®Google Scholar
• Rosati E, Sabatini R, Rampino G, et al. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood. 2009;113:856–865.
   PubMed Web of Science ®Google Scholar